Citi analyst Patrick Donnelly raised the firm’s price target on Qiagen to $60 from $55 and keeps a Buy rating on the shares post the Q4 results. The analyst continues to view the company’s non-COVID portfolio as a position of strength.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on QGEN:
